Breast cancer, Secondary cancers
Results
Phase 2
This trial looked at adding a drug called capivasertib to paclitaxel chemotherapy for .
You pronounce capivasertib as cap-i-va-ser-tib.
This trial was for people whose breast cancer had come back after treatment or spread to other parts of the body.
Cancer Research UK supported this trial. It was open for people to join between 2014 and 2017. The team published the results in 2019.
Recruitment start: 14 May 2014
Recruitment end: 29 June 2017
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Professor Peter Schmid
AstraZeneca
Barts Health NHS Trust
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NIHR Clinical Research Network: Cancer
Queen Mary University of London
This is Cancer Research UK trial number CRUKE/12/051.
Last reviewed: 7 February 2024
CRUK internal database number: 10434
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
